 | ||||||||
| "anti diabetes" | ||||||||
| NEWS | ||||||||
Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ... ... of ITCA 650 at 60 micrograms per day vs. placebo in just over 4,000 patients on a variety of approved standard of care anti-diabetes therapies.
| ||||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.